Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 12/20 | 0.66 |
| ▸ | SIRT6 | Q8N6T7 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058364 | 0.86 | MAPT (0.71) | MAPTSIRT6LMNARECQLALDH1A1 | |
| SCHEMBL213790 | 0.84 | LMNA (0.69) | MAPTSIRT6LMNARECQLALDH1A1 | |
| SCHEMBL213791 | 0.84 | LMNA (0.69) | MAPTSIRT6LMNARECQLALDH1A1 | |
| SCHEMBL77148 | 0.80 | SIRT6 (1.00) | MAPTSIRT6LMNARECQLALDH1A1 | |
| SCHEMBL216810 | 0.80 | MAPT (0.67) | MAPTSIRT6LMNARECQLALDH1A1 | |
| SCHEMBL30565934 | 0.80 | MAPT (0.67) | MAPTSIRT6LMNARECQLALDH1A1 | |
| SCHEMBL2553550 | 0.79 | MAPT (0.72) | MAPTSIRT6LMNARECQLALDH1A1 | |
| SCHEMBL1842221 | 0.79 | MAPT (0.67) | MAPTSIRT6LMNARECQLALDH1A1 | |
| SCHEMBL1811704 | 0.79 | MAPT (0.63) | MAPTSIRT6LMNAALDH1A1HTT | |
| SCHEMBL1843709 | 0.78 | MAPT (0.57) | MAPTSIRT6LMNARECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| EP-2556058-B1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INST (AU) | 2017-06-14 | — | — | EP | disclosed |
| EP-2556058-B1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INST (AU) | 2017-06-14 | — | — | EP | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-05-02 | — | — | US | disclosed |
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-05-02 | — | — | US | disclosed |
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-05-02 | — | — | US | disclosed |
| EP-2556058-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | Peter MacCallum Cancer Institute (AU) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011123890-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011123890-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | NR1H2, NR1H3, NR1I3 | MAPT 4678/4885SIRT6 1519/4885LMNA 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.